Tags - | ABPI

ABPI response to Brexit freight capacity announcement

The Department for Transport has today announced details of the freight capacity it has secured to prepare for a 'no-deal' Brexit.

ABPI response to Jeremy Corbyn speech

In a speech today, Jeremy Corbyn highlighted concerns about the price of medicines, and reiterated Labour's proposals for compulsory licensing.

Analysis: Would ‘Medicines for the Many’ lead to many medicines?

The short answer is, no – but for those wanting a more complete explanation, read on...

ABPI response to NAO report into Brexit and health

The National Audit Office (NAO) has publish a new report – Exiting the EU: supplying the health and social care sectors– into the progress made by the DHSC, working with others, to secure continuity of supply for health and social care sectors should the UK depart the EU without a deal on 31...

ABPI response to Jeremy Corbyn's Conference speech

The ABPI has responded to the Labour leader's 2019 Conference Speech.

New toolkit to help NHS and industry work together

The ABPI has launched new guidance to make sure that joint working between the NHS and industry delivers ‘a triple win’ in benefits for patients, the NHS and companies.

New partnership to tackle Birmingham’s biggest health challenges

A new collaboration to tackle the biggest health challenges faced by the West Midlands’ six million residents will use real-time clinical trials and health data to speed up research and improve cancer care, maternity services, child health, obesity, and dementia.

ABPI comments on 'Operation Yellowhammer' publication

Government has published the documents relating to 'Operation Yellowhammer' with planning assumptions for a 'no-deal' Brexit.

New digital innovation hubs to foster medicine R&D

Health Data Research UK has announced the locations of seven new digital innovation hubs that will help the UK make the most of health-related data for future research and development into new medicines.

NICE CEO Sir Andrew Dillon to step down - ABPI response

NICE has announced that CEO Sir Andrew Dillon is to step down at the end of March next year.

ABPI position on US trade deal and medicines pricing

In response to concerns about the impact a US trade deal would have on medicine pricing, the ABPI continues to emphasise that in the UK, we have very strict rules which control medicine spend.